Exclusive Summary

• First-Mover Market Opportunity: As one of the first generic Nalmefene nasal sprays available globally, it allows partners to become the first supplier in their market, well ahead of the original brand's (OPVEE®) international expansion.
• Superior Clinical Profile for the Fentanyl Crisis: Offers a much longer duration of action than naloxone, effectively reversing overdoses from potent synthetic opioids like fentanyl with a single dose and significantly reducing the risk of re-narcotization.
• Gold-Standard Compliance & Quality Endorsement: The product and manufacturing site are US FDA approved, with a complete US ANDA dossier available. This drastically accelerates the registration process in countries worldwide and serves as the highest guarantee of quality.
• Clear Value-Added Economic Positioning: Compared to naloxone, this product offers superior clinical efficacy and safety, presenting a more reliable and comprehensively cost-effective lifesaving option for payers like governments and emergency services.